Cullinan Oncology LLC Net Assets
Cullinan Oncology LLC net assets. Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has net assets worth $366.17 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($402.98 Million) and total liabilities ($36.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Cullinan Oncology LLC (CGEM) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $366.17 Million |
| % of Total Assets | 90.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -3.91% |
| 10-Year Change | N/A |
| Growth Volatility | 49.76 |
Net Assets of Cullinan Oncology LLC (2012–2025)
Net assets of Cullinan Oncology LLC from 2012 to 2025. This chart illustrates how Cullinan Oncology LLC's net assets have evolved over time, based on quarterly financial data. See Cullinan Oncology LLC net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Cullinan Oncology LLC (2012–2025)
The table below shows the annual net assets of Cullinan Oncology LLC from 2012 to 2025. For live market cap and overall valuation, see market cap of Cullinan Oncology LLC.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $408.73 Million | -30.76% |
| 2024-12-31 | $590.33 Million | +30.06% |
| 2023-12-31 | $453.89 Million | -15.16% |
| 2022-12-31 | $535.03 Million | +25.78% |
| 2021-12-31 | $425.37 Million | +112.35% |
| 2020-12-31 | $200.31 Million | +601.93% |
| 2019-12-31 | $-39.91 Million | -93.26% |
| 2018-12-31 | $-20.65 Million | -3492.24% |
| 2016-12-31 | $-574.85K | +53.82% |
| 2015-12-31 | $-1.24 Million | -9.65% |
| 2014-12-31 | $-1.14 Million | -12.99% |
| 2013-12-31 | $-1.00 Million | -221.01% |
| 2012-12-31 | $-313.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cullinan Oncology LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58811900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cullinan Oncology LLC Net Assets Breakdown (December 2025)
Cullinan Oncology LLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $1.02 Million | 0.25% |
| Other Components | $995.82 Million | 243.64% |
| Total Equity | $408.73 Million | 100.00% |
Cullinan Oncology LLC Competitors by Market Cap
The table below lists competitors of Cullinan Oncology LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TOA Paint (Thailand) Public Company Limited
BK:TOA
|
$894.28 Million |
|
GrocerIQ, Inc
NYSE:WPFHD
|
$894.41 Million |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
$894.77 Million |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
$895.17 Million |
|
Major Drilling Group International
TO:MDI
|
$894.11 Million |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
$893.70 Million |
|
Sprinklr Inc
NYSE:CXM
|
$893.10 Million |
|
Jiajiayue Group Co Ltd
SHG:603708
|
$892.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cullinan Oncology LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 590,328,000 to 408,730,000, a change of -181,598,000 (-30.8%).
- Net loss of 219,879,000 reduced equity.
- Other comprehensive income increased equity by 1,153,000.
- Other factors increased equity by 37,128,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-219.88 Million | -53.8% |
| Other Comprehensive Income | $1.15 Million | +0.28% |
| Other Changes | $37.13 Million | +9.08% |
| Total Change | $- | -30.76% |
Book Value vs Market Value Analysis
This analysis compares Cullinan Oncology LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-25.81 | $15.75 | x |
| 2019-12-31 | $-40.06 | $15.75 | x |
| 2020-12-31 | $4.57 | $15.75 | x |
| 2021-12-31 | $9.59 | $15.75 | x |
| 2022-12-31 | $11.47 | $15.75 | x |
| 2023-12-31 | $10.92 | $15.75 | x |
| 2024-12-31 | $10.98 | $15.75 | x |
| 2025-12-31 | $6.92 | $15.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cullinan Oncology LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-53.80%) is below the historical average (-11.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-604.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.01K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $14.97K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-259.22K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.12 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.96 Million |
| 2020 | -25.55% | -268.43% | 0.09x | 1.08x | $-70.75 Million |
| 2021 | -15.30% | -343.35% | 0.04x | 1.03x | $-107.54 Million |
| 2022 | 20.79% | 0.00% | 0.00x | 1.05x | $57.71 Million |
| 2023 | -33.76% | 0.00% | 0.00x | 1.07x | $-198.53 Million |
| 2024 | -28.35% | 0.00% | 0.00x | 1.05x | $-226.42 Million |
| 2025 | -53.80% | 0.00% | 0.00x | 1.10x | $-260.75 Million |
Industry Comparison
This section compares Cullinan Oncology LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cullinan Oncology LLC (CGEM) | $366.17 Million | 0.00% | 0.10x | $894.21 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more